BNBX.US Applied DNA Sciences, Inc.
- Market cap
- USD 558K
- P/E
- 0.0x
- P/B
- 0.05x
- ROE
- -404.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Mar 2026.
Is BNBX.US undervalued?
Graham numberThe Graham number of Applied DNA Sciences, Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Applied DNA Sciences, Inc. fundamental analysis
No fundamental analysis for Applied DNA Sciences, Inc. yet.
Applied DNA Sciences, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Applied DNA Sciences, Inc.
BNB Plus Corp. provides digital asset treasury services. The company offers real-time data tracking of treasury performance and market indicators. The company, through its subsidiaries, also develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the Americas, Europe, Asia, and internationally. The company engages in the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based ther…
Full company profileApplied DNA Sciences, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Applied DNA Sciences, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 9.03M | 18.2M | 13.4M | 3.43M | 2.14M | 3.18M |
| Gross Profit | 4.48M | 5.05M | 5.53M | 1.02M | 839K | 2.15M |
| Operating Income | -13.3M | -14.0M | -11.0M | -14.0M | -16.0M | -31.3M |
| EBITDA | -11.7M | -6.98M | -8.66M | -6.39M | -15.3M | -50.4M |
| Net Income | -14.3M | -8.27M | -9.95M | -6.99M | -15.2M | -50.5M |
| EPS | -28,630 | -9,614 | -571 | -66 | -29 | -5.19 |
| Balance Sheet | ||||||
| Total Assets | 14.4M | 22.3M | 13.7M | 12.8M | 4.44M | 13.6M |
| Total Liabilities | 3.30M | 9.36M | 8.78M | 3.82M | 2.50M | 1.50M |
| Shareholders' Equity | 11.1M | 12.9M | 4.95M | 9.14M | 2.30M | 12.5M |
| Cash & Short-term Investments | 6.55M | 15.2M | 7.15M | 6.43M | 1.67M | 949K |
| Total Debt | - | - | 1.24M | 739K | 193K | - |
| Cash Flow | ||||||
| Operating Cash Flow | -13.4M | -8.98M | -6.22M | -13.7M | -12.5M | -15.2M |
| Capital Expenditure | 2.55M | 490K | 78.4K | 408K | 313K | 6.00 |
| Free Cash Flow | -15.9M | -9.47M | -6.30M | -14.1M | -12.8M | -15.2M |
| Ratios | ||||||
| ROE | -128.5% | -64.0% | -200.9% | -76.5% | -657.8% | -404.0% |
| ROA | -99.1% | -37.1% | -72.9% | -54.7% | -341.7% | -370.5% |
| Net Profit Margin | -158.3% | -45.5% | -74.4% | -203.8% | -709.5% | -1,589.1% |
| Debt to Equity | - | - | 0.25x | 0.08x | 0.08x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Applied DNA Sciences, Inc. dividends
Applied DNA Sciences, Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:15 on Jun 2, 2025.
Who owns Applied DNA Sciences, Inc.
- Insiders 5.64%
- Institutions 7.10%
- Public & others 87.26%
- Shares outstanding 6.20M
- Free float 5.93M
Top funds holding BNBX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 26.1K | 0.42% | -61.69% | Jun 2026 |
| Fidelity Series Total Market Index | 5.08K | 0.08% | 0.00% | Jun 2026 |
| Spartan Total Market Index Pool A1 | 3.09K | 0.05% | 0.00% | Jun 2026 |
Top institutions holding BNBX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Intrinsic Edge Capital Management, LLC | 309K | 4.99% | +6.67% | Jun 2026 |
| Galaxy Digital Inc. | 121K | 1.94% | 0.00% | Mar 2026 |
| Geode Capital Management, LLC | 76.6K | 1.24% | +166.14% | Mar 2026 |
| Citadel Advisors Llc | 52.2K | 0.84% | -15.52% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 28.7K | 0.46% | 0.00% | Mar 2026 |
| Vanguard Fiduciary Trust Co | 16.7K | 0.27% | 0.00% | Mar 2026 |
| XTX Topco Ltd | 13.7K | 0.22% | 0.00% | Mar 2026 |
| Sabby Management LLC | 13.5K | 0.22% | -74.92% | Mar 2026 |
| Virtu Financial LLC | 10.5K | 0.17% | 0.00% | Mar 2026 |
| UBS Group AG | 8.62K | 0.14% | +108.49% | Mar 2026 |
| Tower Research Capital LLC | 3.24K | 0.05% | -10.00% | Mar 2026 |
| Vanguard Capital Management, LLC | 386.00 | 0.01% | 0.00% | Mar 2026 |
| SBI Securities Co Ltd | 145.00 | 0.00% | -0.68% | Mar 2026 |
| BlackRock Inc | 4.00 | 0.00% | 0.00% | Mar 2026 |
| Advisor Group Holdings, Inc. | 4.00 | 0.00% | +33.33% | Mar 2026 |
| Morgan Stanley - Brokerage Accounts | 3.00 | 0.00% | 0.00% | Mar 2026 |
| Dakota Community Bank & Trust NA | 3.00 | 0.00% | +50.00% | Jun 2026 |
| Wells Fargo & Co | 2.00 | 0.00% | 0.00% | Mar 2026 |
| Rockefeller Capital Management L.P. | 2.00 | 0.00% | 0.00% | Mar 2026 |
| Integrated Wealth Concepts LLC | 2.00 | 0.00% | 0.00% | Jun 2026 |
Applied DNA Sciences, Inc. company profile
- Company name
- Applied DNA Sciences, Inc.
- Ticker
- BNBX.US
- Exchange
- USA Stocks
- Listed since
- Jul 15, 2003
- Sector
- Financial Services
- Industry
- Health Care Equipment & Supplies
- Employees
- 26
- Fiscal year end
- September
- Address
- 50 Health Sciences Drive, Stony Brook, NY, United States, 11790
- Phone
- 631 240 8800
- Website
- bnbx.io
About Applied DNA Sciences, Inc.
BNB Plus Corp. provides digital asset treasury services. The company offers real-time data tracking of treasury performance and market indicators. The company, through its subsidiaries, also develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the Americas, Europe, Asia, and internationally. The company engages in the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and nucleic acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP, and LineaIVT, as well as the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. BNB Plus Corp. was formerly known as Applied DNA Sciences, Inc. and changed its name to BNB Plus Corp. in November 2025. The company was founded in 1983 and is based in Stony Brook, New York.
Applied DNA Sciences, Inc. management
4- Mr. Clay D. Shorrock Esq., J.D.President & CEO · born 1984
- Ms. Beth M. Jantzen CPAChief Financial Officer · born 1976
- Ms. Judith MurrahStrategic Transition Advisor, Secretary & Director · born 1958
- Mr. Sanjay M. HurryExecutive Director of Investor Relations & Corporate Communications